178 related articles for article (PubMed ID: 22711601)
1. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
[TBL] [Abstract][Full Text] [Related]
2. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Venkatesh HS; Chaumeil MM; Ward CS; Haas-Kogan DA; James CD; Ronen SM
Neuro Oncol; 2012 Mar; 14(3):315-25. PubMed ID: 22156546
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
Liu LL; Long ZJ; Wang LX; Zheng FM; Fang ZG; Yan M; Xu DF; Chen JJ; Wang SW; Lin DJ; Liu Q
Mol Cancer Res; 2013 Nov; 11(11):1326-36. PubMed ID: 24008673
[TBL] [Abstract][Full Text] [Related]
5. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
[TBL] [Abstract][Full Text] [Related]
6. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
[TBL] [Abstract][Full Text] [Related]
7. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
[TBL] [Abstract][Full Text] [Related]
8. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Márk Á; Hajdu M; Váradi Z; Sticz TB; Nagy N; Csomor J; Berczi L; Varga V; Csóka M; Kopper L; Sebestyén A
BMC Cancer; 2013 May; 13():250. PubMed ID: 23693095
[TBL] [Abstract][Full Text] [Related]
9. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract][Full Text] [Related]
10. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin controls glucose consumption and redox balance in human Sertoli cells.
Jesus TT; Oliveira PF; Silva J; Barros A; Ferreira R; Sousa M; Cheng CY; Silva BM; Alves MG
Fertil Steril; 2016 Mar; 105(3):825-833.e3. PubMed ID: 26698679
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
Allen E; Miéville P; Warren CM; Saghafinia S; Li L; Peng MW; Hanahan D
Cell Rep; 2016 May; 15(6):1144-60. PubMed ID: 27134166
[TBL] [Abstract][Full Text] [Related]
15. STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer.
Wu F; Gao P; Wu W; Wang Z; Yang J; Di J; Jiang B; Su X
J Exp Clin Cancer Res; 2018 Jul; 37(1):144. PubMed ID: 29996891
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
[TBL] [Abstract][Full Text] [Related]
17. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
[TBL] [Abstract][Full Text] [Related]
19. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
20. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]